2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5482 Dual epigenetic targeting of ASXL1-mutant chronic myelomonocytic leukemia with EP31670

Moritz Binder, MD, MPH, Terra Lasho, PhD2, Jenna Fernandez, Ph.D.3, Meher Gayatri Bolisetti, PhD4, Matthew Smith5, Esraa Keewan6, Wazim Mohammed Ismail, Ph.D.7, Amelia Mazzone, Ph.D.8, Christy Finke, BS9, Pankaj Pradeep10, Abhishek Avinash Mangaonkar, MBBS11, Nickolas Steinauer, M.D., Ph.D.12, Huihuang Yan, PhD13, Liguo Wang14, Alexandre Gaspar-Maia, PhD15, Jing Zhang, MD16, Mrinal M. Patnaik, MD, MBBS17
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 University of Wisconsin, Madison, Wisconsin, United States, University of Wisconsin, Madison, Wisconsin, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 University of Wisconsin, Madison, Wisconsin, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 University of Wisconsin, Madison, Wisconsin, United States
17 Mayo Clinic, Rochester, Minnesota, United States

Introduction: ASXL1-mutant (ASXL1mt) Chronic Myelomonocytic Leukemia (CMML) is an aggressive myeloid neoplasm for which currently no effective targeted therapies exist. It is characterized by increased proliferation, resistance to DNA methyltransferase inhibitors, and poor survival outcomes. Epigenetic remodeling, up-regulation of leukemogenic driver genes, and increased activity of BRD4/p300-binding enhancers are hallmarks of ASXL1mt CMML (Binder et al. Nat Comm 2022). Here, we investigate the therapeutic effects of dual BRD4/p300 inhibition with EP31670 in vitro and in vivo.

Methods: For the in vitro experiments, cells were plated in methylcellulose with recombinant human cytokines (duplicates with a range of EP31670 concentrations). After 10 days, colonies were characterized by morphology and quantified using a 2x2 mm gridded counting surface. IC50 values were generated using non-linear regression. Cells were plated in liquid culture: no drug versus 31nM EP31670 for 24 hours and assessed by RT-qPCR for gene expression (HOXA6, HOXA9). In vivo experiments included the Asxl1 fl/fl NrasG12D-Vav1-Cre genetically engineered mouse model (NA-GEMM; You et al. Blood 2022). Recipient mice were transplanted with cells from the NA-GEMM. Post-transplant (2 weeks), mice were randomly divided into two cohorts receiving vehicle (n=8) or EP31670 (n=15) (30mg/kg). The absolute number of leukemia cells in the peripheral blood was monitored weekly. When the vehicle group was moribund, they were sacrificed along with EP31670-treated mice. Leukemia cells (CD45.2+Mac1+) were flow-sorted and analyzed for expression of Hoxa6, Hoxa9, Hoxa10, and Meis1. The remaining mice were continuously treated and closely monitored until moribund to generate Kaplan-Meier plots.

Results: Epigenetic profiling in 40 CMML patients (19 ASXL1mt and 21 wt) revealed increased accessibility of enhancers driving the overexpression of HOXA6, HOXA9, and MEIS1. Among other transcriptional regulators, BRD4 and p300 emerged as potential therapeutic targets. In progenitor colony forming assays, EP31670 demonstrated activity at low nanomolar concentrations with a strong preferential therapeutic effect in ASXL1mt (mean IC50=29nM, n=10) compared to ASXL1wt (mean IC50=61nM, p=0.0077, n=6) and normal controls (mean IC50=174nM, p<0.0001, n=2). Exposure of ASXLmt bone marrow mononuclear cells to 31nM of EP31670 for 48 hours led to the down-regulation of the target genes HOXA6 (log2-fold change -0.40, p=0.0485, n=6) and HOXA9 (log2-fold change -0.35, p=0.0267, n=6). Morphologically, treatment with EP31670 was associated with increased differentiation (increased blast forming units-erythroid; BFU-E) and colony organization in ASXL1mt (compared to wt). In contrast, MENIN inhibition with ziftomenib (K0-539) did not demonstrate differential therapeutic effects between ASXL1mt and wt (1658nM versus 1147nM, p=0.3851, n=20). In vivo, EP31670 led to therapeutic effects at low nanomolar concentrations (mean IC50=14nM). Drug treatment (compared to vehicle) significantly slowed down the leukemia progression as measured by the peripheral blood absolute monocyte count, induced down-regulation of Hoxa6, Hoxa9, Hoxa10, and Meis1 (p<0.0100), and demonstrated survival benefit (median 42 versus 22 days, p<0.0100).

Conclusions: ASXL1mt CMML is characterized by the up-regulation of leukemogenic driver genes in the HOXA cluster secondary to the activation of genotype-specific enhancers via BRD4 and p300. In vitro, the dual BRD4/p300 inhibitor EP31670 induces therapeutic responses at low nanomolar drug concentrations and leads to normalization of colony morphology. In vivo, the drug controls peripheral blood monocytosis and provides survival benefit. In both model systems the drug reverses the up-regulation of several key leukemogenic driver genes, suggesting successful epigenetic reprogramming and making EP31670 a leading candidate for the first targeted epigenetic therapy for ASXL1mt chronic myeloid neoplasms. The evaluation of safety and tolerability of EP31670 in this patient population is under way (NCT05488548).

Moritz Binder, MD, MPH: No relevant conflicts of interest to declare.